One Arizona Agreement
Opioid Settlement Funds
The pharmaceutical industry is being held accountable for its role in perpetuating the opioid epidemic. National investigations and litigation against pharmaceutical manufacturers, distributors, marketing companies, pharmacy chains, and pharmacy benefits managers has secured more than $50 billion across at least 12 settlements so far. Arizona’s $1.215 billion share of the settlement funds has been determined by the impact of the crisis on the state and its population.
|
Funds already distributed McKinsey |
⟶ |
Funds being distributed now Distributor |
⟶ |
Possible future fund distribution Purdue |
One Arizona Agreement
To effectively distribute $1.215 billion in opioid settlement funds over 18 years, the state, counties, cities and towns reached an agreement to disburse funds based on population and severity of harm.
- The State will receive 44 percent of the total, $535 million
- The counties will receive 56 percent, or $680 million, to distribute to the cities and towns within the region
National Opioid Settlement Projected TotalsReflects current totals as of September 30, 2025 |
|||||
|---|---|---|---|---|---|
|
Name Of Settlement |
|
Total Arizona Share |
44% State Share |
56% Local Share |
Years of Payout |
|
Distributor* (McKesson Corp.; Cardinal Health, Inc; and Cencora, Inc.) |
$451,066,759.58 |
$198,469,374.22 |
$252,597,385.36 |
18 |
|
|
Janssen |
$103,292,344.59 |
$45,448,631.62 |
$57,843,712.97 |
10 |
|
|
Mallinckrodt |
$7,910,731.34 |
$3,480,721.79 |
$4,430,009.55 |
2 |
|
|
Teva |
$92,991,844.50 |
$40,916,411.58 |
$52,075,432.92 |
13 |
|
|
Allergan |
$51,232,770.16 |
$22,542,418.87 |
$28,690,351.29 |
7 |
|
|
Walmart |
$64,201,427.97 |
$28,248,628.31 |
$35,952,799.66 |
6 |
|
|
CVS |
$113,363,593.06 |
$49,879,980.95 |
$63,483,612.11 |
10 |
|
|
Walgreens |
$123,297,961.75 |
$54,251,103.17 |
$69,046,858.58 |
15 |
|
|
Endo International plc |
$14,021,221.04 |
$6,169,337.26 |
$7,851,883.78 |
1 |
|
|
Kroger |
$68,500,000.00 |
$30,140,000.00 |
$38,360,000.00 |
9 |
|
|
Purdue** |
$108,179,642.18 |
$47,599,042.56 |
$60,580,599.62 |
15 |
|
| Secondary Manufacturers (Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus)** | $15,161,054.00 | $7,550,863.76 | $9,610,190.24 | Varies | |
|
TOTAL |
$1,215,219,350.17 |
$534,696,514.07 |
$680,522,836.10 |
|
|
**Settlements subject to final court approval; projections may change when finalized.
*Each of the three defendants is responsible for 1/3 of the settlement payments.
DEEP DIVE: Total anticipated allocations
Prevention, treatment and education
The One Arizona Agreement outlines approved purposes for the opioid settlement funds for counties, cities and towns to follow.
81,083 people died from an opioid overdose in 2023
-Centers for Disease Control and Prevention
Treatment
- Treat opioid-use disorder, support people in treatment and recovery, and connect people to care
- Implement evidence-based, evidence-informed or promising programs and strategies
- Address the needs of persons in the criminal justice system
- Support pregnant or parenting women and their families, especially babies affected by neonatal abstinence syndrome which causes newborns to suffer withdrawal symptoms
Prevention
- Curb over-prescribing by training providers on appropriate prescribing and dispensing practices
- Aim campaigns at discouraging misuse of opioids
- Reduce or stop overdose deaths and other opioid-related harms such as homelessness, unemployment and destruction of families
Additional Strategies
- Support first responders with training on appropriate practices and precautions when dealing with fentanyl or other drugs
- Leadership, planning, and coordination including needs-identification, government dashboards to track opioid metrics, and investments in the infrastructure or staffing needed to support effective programs